Sign In

Login

Password

Forgot Password ? Sign Up

Mięśniakomięsak gładkokomórkowy (Polish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Mięśniakomięsak gładkokomórkowy" in Polish language version.

refsWebsite
Global rank Polish rank
30nih.gov
4th place
7th place
23doi.org
2nd place
6th place
2google.pl
low place
557th place
1researchgate.net
120th place
180th place

doi.org

  • F. Duffaud, I. Ray-Coquard, S. Salas, P. Pautier. Recent advances in understanding and managing leiomyosarcomas. „F1000Prime Rep”. 7, s. 55, 2015. DOI: 10.12703/P7-55. PMID: 26097728. 
  • M. Miettinen. Smooth muscle tumors of soft tissue and non-uterine viscera: biology and prognosis. „Mod Pathol”. 27 Suppl 1, s. S17-29, Jan 2014. DOI: 10.1038/modpathol.2013.178. PMID: 24384850. 
  • B. Purgina, U.N. Rao, M. Miettinen, L. Pantanowitz. AIDS-Related EBV-Associated Smooth Muscle Tumors: A Review of 64 Published Cases. „Patholog Res Int”. 2011, s. 561548, 2011. DOI: 10.4061/2011/561548. PMID: 21437186. 
  • J.H. Francis, R.A. Kleinerman, J.M. Seddon, D.H. Abramson. Increased risk of secondary uterine leiomyosarcoma in hereditary retinoblastoma. „Gynecol Oncol”. 124 (2), s. 254–259, Feb 2012. DOI: 10.1016/j.ygyno.2011.10.019. PMID: 22027510. 
  • S. Ognjanovic, M. Olivier, T.L. Bergemann, P. Hainaut. Sarcomas in TP53 germline mutation carriers: a review of the IARC TP53 database. „Cancer”. 118 (5), s. 1387–1396, Mar 2012. DOI: 10.1002/cncr.26390. PMID: 21837677. 
  • A.J. Bathan, A. Constantinidou, S.M. Pollack, R.L. Jones. Diagnosis, prognosis, and management of leiomyosarcoma: recognition of anatomic variants. „Curr Opin Oncol”. 25 (4), s. 384–389, Jul 2013. DOI: 10.1097/CCO.0b013e3283622c77. PMID: 23635801. 
  • N. Pervaiz, N. Colterjohn, F. Farrokhyar, R. Tozer i inni. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. „Cancer”. 113 (3), s. 573–581, Aug 2008. DOI: 10.1002/cncr.23592. PMID: 18521899. 
  • P.J. Woll, P. Reichardt, A. Le Cesne, S. Bonvalot i inni. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. „Lancet Oncol”. 13 (10), s. 1045–1054, Oct 2012. DOI: 10.1016/S1470-2045(12)70346-7. PMID: 22954508. 
  • M.L. Hensley, J.K. Wathen, R.G. Maki, D.M. Araujo i inni. Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005). „Cancer”. 119 (8), s. 1555–1561, Apr 2013. DOI: 10.1002/cncr.27942. PMID: 23335221. 
  • S. Sleijfer, M. Ouali, M. van Glabbeke, A. Krarup-Hansen i inni. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). „Eur J Cancer”. 46 (1), s. 72–83, Jan 2010. DOI: 10.1016/j.ejca.2009.09.022. PMID: 19853437. 
  • J.O. Bay, I. Ray-Coquard, J. Fayette, S. Leyvraz i inni. Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. „Int J Cancer”. 119 (3), s. 706–711, Aug 2006. DOI: 10.1002/ijc.21867. PMID: 16496406. 
  • K.M. Leu, L.J. Ostruszka, D. Shewach, M. Zalupski i inni. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. „J Clin Oncol”. 22 (9), s. 1706–1712, May 2004. DOI: 10.1200/JCO.2004.08.043. PMID: 15117993. 
  • M.L. Hensley, J.A. Blessing, K. Degeest, O. Abulafia i inni. Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. „Gynecol Oncol”. 109 (3), s. 323–328, Jun 2008. DOI: 10.1016/j.ygyno.2008.02.024. PMID: 18394689. 
  • R.G. Maki, J.K. Wathen, S.R. Patel, D.A. Priebat i inni. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. „J Clin Oncol”. 25 (19), s. 2755–2763, Jul 2007. DOI: 10.1200/JCO.2006.10.4117. PMID: 17602081. 
  • P. Pautier, A. Floquet, N. Penel, S. Piperno-Neumann i inni. Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study). „Oncologist”. 17 (9), s. 1213–1220, 2012. DOI: 10.1634/theoncologist.2011-0467. PMID: 22907974. 
  • X. García-Del-Muro, A. López-Pousa, J. Maurel, J. Martín i inni. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. „J Clin Oncol”. 29 (18), s. 2528–2533, Jun 2011. DOI: 10.1200/JCO.2010.33.6107. PMID: 21606430. 
  • A. Le Cesne, J.Y. Blay, I. Judson, A. Van Oosterom i inni. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. „J Clin Oncol”. 23 (3), s. 576–584, Jan 2005. DOI: 10.1200/JCO.2005.01.180. PMID: 15659504. 
  • B.L. Samuels, S. Chawla, S. Patel, M. von Mehren i inni. Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study. „Ann Oncol”. 24 (6), s. 1703–1709, Jun 2013. DOI: 10.1093/annonc/mds659. PMID: 23385197. 
  • S. Sleijfer, I. Ray-Coquard, Z. Papai, A. Le Cesne i inni. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). „J Clin Oncol”. 27 (19), s. 3126–3132, Jul 2009. DOI: 10.1200/JCO.2008.21.3223. PMID: 19451427. 
  • W.T. van der Graaf, J.Y. Blay, S.P. Chawla, D.W. Kim i inni. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. „Lancet”. 379 (9829), s. 1879–1886, May 2012. DOI: 10.1016/S0140-6736(12)60651-5. PMID: 22595799. 
  • N. Penel, A. Italiano, N. Isambert, E. Bompas i inni. Factors affecting the outcome of patients with metastatic leiomyosarcoma treated with doxorubicin-containing chemotherapy. „Ann Oncol”. 21 (6), s. 1361–1365, Jun 2010. DOI: 10.1093/annonc/mdp485. PMID: 19880438. 
  • C. Svarvar, T. Böhling, O. Berlin, P. Gustafson i inni. Clinical course of nonvisceral soft tissue leiomyosarcoma in 225 patients from the Scandinavian Sarcoma Group. „Cancer”. 109 (2), s. 282–291, Jan 2007. DOI: 10.1002/cncr.22395. PMID: 17154171. 
  • J.A. Abraham, M.J. Weaver, J.L. Hornick, D. Zurakowski i inni. Outcomes and prognostic factors for a consecutive case series of 115 patients with somatic leiomyosarcoma. „J Bone Joint Surg Am”. 94 (8), s. 736–744, Apr 2012. DOI: 10.2106/JBJS.K.00460. PMID: 22517390. 

google.pl

books.google.pl

nih.gov

ncbi.nlm.nih.gov

  • P. Gustafson, H. Willén, B. Baldetorp, M. Fernö i inni. Soft tissue leiomyosarcoma. A population-based epidemiologic and prognostic study of 48 patients, including cellular DNA content. „Cancer”. 70 (1), s. 114–119, Jul 1992. PMID: 1606532. 
  • F. Duffaud, I. Ray-Coquard, S. Salas, P. Pautier. Recent advances in understanding and managing leiomyosarcomas. „F1000Prime Rep”. 7, s. 55, 2015. DOI: 10.12703/P7-55. PMID: 26097728. 
  • M. Miettinen. Smooth muscle tumors of soft tissue and non-uterine viscera: biology and prognosis. „Mod Pathol”. 27 Suppl 1, s. S17-29, Jan 2014. DOI: 10.1038/modpathol.2013.178. PMID: 24384850. 
  • B. Purgina, U.N. Rao, M. Miettinen, L. Pantanowitz. AIDS-Related EBV-Associated Smooth Muscle Tumors: A Review of 64 Published Cases. „Patholog Res Int”. 2011, s. 561548, 2011. DOI: 10.4061/2011/561548. PMID: 21437186. 
  • J.H. Francis, R.A. Kleinerman, J.M. Seddon, D.H. Abramson. Increased risk of secondary uterine leiomyosarcoma in hereditary retinoblastoma. „Gynecol Oncol”. 124 (2), s. 254–259, Feb 2012. DOI: 10.1016/j.ygyno.2011.10.019. PMID: 22027510. 
  • S. Ognjanovic, M. Olivier, T.L. Bergemann, P. Hainaut. Sarcomas in TP53 germline mutation carriers: a review of the IARC TP53 database. „Cancer”. 118 (5), s. 1387–1396, Mar 2012. DOI: 10.1002/cncr.26390. PMID: 21837677. 
  • A.D. Pinheiro, D.C. Wright. Naloxone eliminates passive avoidance retention deficits produced by pretest exposure to novelty in rats. „Behav Neural Biol”. 55 (3), s. 270–288, May 1991. PMID: 1647763. 
  • A.J. Bathan, A. Constantinidou, S.M. Pollack, R.L. Jones. Diagnosis, prognosis, and management of leiomyosarcoma: recognition of anatomic variants. „Curr Opin Oncol”. 25 (4), s. 384–389, Jul 2013. DOI: 10.1097/CCO.0b013e3283622c77. PMID: 23635801. 
  • J.C. Yang, A.E. Chang, A.R. Baker, W.F. Sindelar i inni. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. „J Clin Oncol”. 16 (1), s. 197–203, Jan 1998. PMID: 9440743. 
  • N. Pervaiz, N. Colterjohn, F. Farrokhyar, R. Tozer i inni. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. „Cancer”. 113 (3), s. 573–581, Aug 2008. DOI: 10.1002/cncr.23592. PMID: 18521899. 
  • P.J. Woll, P. Reichardt, A. Le Cesne, S. Bonvalot i inni. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. „Lancet Oncol”. 13 (10), s. 1045–1054, Oct 2012. DOI: 10.1016/S1470-2045(12)70346-7. PMID: 22954508. 
  • M.L. Hensley, J.K. Wathen, R.G. Maki, D.M. Araujo i inni. Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005). „Cancer”. 119 (8), s. 1555–1561, Apr 2013. DOI: 10.1002/cncr.27942. PMID: 23335221. 
  • M. Van Glabbeke, A.T. van Oosterom, J.W. Oosterhuis, H. Mouridsen i inni. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. „J Clin Oncol”. 17 (1), s. 150–157, Jan 1999. PMID: 10458228. 
  • S. Sleijfer, M. Ouali, M. van Glabbeke, A. Krarup-Hansen i inni. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). „Eur J Cancer”. 46 (1), s. 72–83, Jan 2010. DOI: 10.1016/j.ejca.2009.09.022. PMID: 19853437. 
  • M.L. Hensley, R. Maki, E. Venkatraman, G. Geller i inni. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. „J Clin Oncol”. 20 (12), s. 2824–2831, Jun 2002. PMID: 12065559. 
  • J.O. Bay, I. Ray-Coquard, J. Fayette, S. Leyvraz i inni. Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. „Int J Cancer”. 119 (3), s. 706–711, Aug 2006. DOI: 10.1002/ijc.21867. PMID: 16496406. 
  • K.M. Leu, L.J. Ostruszka, D. Shewach, M. Zalupski i inni. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. „J Clin Oncol”. 22 (9), s. 1706–1712, May 2004. DOI: 10.1200/JCO.2004.08.043. PMID: 15117993. 
  • M.L. Hensley, J.A. Blessing, K. Degeest, O. Abulafia i inni. Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. „Gynecol Oncol”. 109 (3), s. 323–328, Jun 2008. DOI: 10.1016/j.ygyno.2008.02.024. PMID: 18394689. 
  • R.G. Maki, J.K. Wathen, S.R. Patel, D.A. Priebat i inni. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. „J Clin Oncol”. 25 (19), s. 2755–2763, Jul 2007. DOI: 10.1200/JCO.2006.10.4117. PMID: 17602081. 
  • P. Pautier, A. Floquet, N. Penel, S. Piperno-Neumann i inni. Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study). „Oncologist”. 17 (9), s. 1213–1220, 2012. DOI: 10.1634/theoncologist.2011-0467. PMID: 22907974. 
  • E.C. Borden, D.A. Amato, C. Rosenbaum, H.T. Enterline i inni. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. „J Clin Oncol”. 5 (6), s. 840–850, Jun 1987. PMID: 3585441. 
  • X. García-Del-Muro, A. López-Pousa, J. Maurel, J. Martín i inni. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. „J Clin Oncol”. 29 (18), s. 2528–2533, Jun 2011. DOI: 10.1200/JCO.2010.33.6107. PMID: 21606430. 
  • A. Le Cesne, J.Y. Blay, I. Judson, A. Van Oosterom i inni. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. „J Clin Oncol”. 23 (3), s. 576–584, Jan 2005. DOI: 10.1200/JCO.2005.01.180. PMID: 15659504. 
  • B.L. Samuels, S. Chawla, S. Patel, M. von Mehren i inni. Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study. „Ann Oncol”. 24 (6), s. 1703–1709, Jun 2013. DOI: 10.1093/annonc/mds659. PMID: 23385197. 
  • S. Sleijfer, I. Ray-Coquard, Z. Papai, A. Le Cesne i inni. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). „J Clin Oncol”. 27 (19), s. 3126–3132, Jul 2009. DOI: 10.1200/JCO.2008.21.3223. PMID: 19451427. 
  • W.T. van der Graaf, J.Y. Blay, S.P. Chawla, D.W. Kim i inni. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. „Lancet”. 379 (9829), s. 1879–1886, May 2012. DOI: 10.1016/S0140-6736(12)60651-5. PMID: 22595799. 
  • N. Penel, A. Italiano, N. Isambert, E. Bompas i inni. Factors affecting the outcome of patients with metastatic leiomyosarcoma treated with doxorubicin-containing chemotherapy. „Ann Oncol”. 21 (6), s. 1361–1365, Jun 2010. DOI: 10.1093/annonc/mdp485. PMID: 19880438. 
  • E. Stoeckle, J.M. Coindre, S. Bonvalot, G. Kantor i inni. Prognostic factors in retroperitoneal sarcoma: a multivariate analysis of a series of 165 patients of the French Cancer Center Federation Sarcoma Group. „Cancer”. 92 (2), s. 359–368, Jul 2001. PMID: 11466691. 
  • C. Svarvar, T. Böhling, O. Berlin, P. Gustafson i inni. Clinical course of nonvisceral soft tissue leiomyosarcoma in 225 patients from the Scandinavian Sarcoma Group. „Cancer”. 109 (2), s. 282–291, Jan 2007. DOI: 10.1002/cncr.22395. PMID: 17154171. 
  • J.A. Abraham, M.J. Weaver, J.L. Hornick, D. Zurakowski i inni. Outcomes and prognostic factors for a consecutive case series of 115 patients with somatic leiomyosarcoma. „J Bone Joint Surg Am”. 94 (8), s. 736–744, Apr 2012. DOI: 10.2106/JBJS.K.00460. PMID: 22517390. 

researchgate.net